From Cytotrophoblast to Syncytiotrophoblast

• Conditions: Syncytiotrophoblast

• Registration Number: NCT02368821
• Lead Sponsor: Meir Medical Center

Brief Summary

A deeper understanding of the syncytiotrophoblast development processes and its properties may allow a better understanding of the placenta pathological process for the development of treatment models for the relevant pregnancy complications.The aim of this study is to compare telomere length, aggregate formation, and senescence markers in placentas from complicated pregnancy with placentas from normal pregnancy.

Detailed Description

Protocol summary No. 2 for research 0202-14 of date: 22/11/2014. Rationale for the research A deeper understanding of the syncytiotrophoblast development processes and its properties may allow a better understanding of the placenta pathological process for the development of treatment models for the relevant pregnancy complications.

The aim of this study is to compare telomere length, aggregate formation, and senescence markers in the syncytiotrophoblast of placentas from complicated pregnancy with placentas from normal pregnancy.

Telomere lenght and aggregate formation will be assessed by the fluorescent intensity of telomere FISH.

Senescence will be assessed by immunohistochemistry for the markers - SAHF, cyclin dependent kinase inhibitors p16/p21, HLAX, ERVWE1, SA-B-gal.

The study groups

1. A retrospective arm - paraffin blocks which were collected over the years from placentas from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete) will be compared to blocks of placentas from normal pregnancies.

2. The prospective arm - placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete) . Will be compared to placentas of normal pregnancies.

3. A laboratory model based on human placenta cell cultures

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Status Verified: 2015-01
• Study First Submitted: 2015-01-15
• Study First Submitted QC: 2015-02-15
• Last Update Submitted: 2015-02-22
• Study First Posted: 2015-02-23
• Last Update Posted: 2015-02-24
• Study Start: 2015-03
• Primary Completion: 2017-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

• placentas from normal and complicated pregnancy

Read More

Exclusion Criteria

• women consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Length of telomere and senescence markers amount in the placentas.	2 years